Compare Mesoblast Limited (MESO) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Symbotic Inc — how do they compare? Mesoblast Limited trades at $16.39 (market cap $2.17B), while Symbotic Inc trades at $42.98 (market cap $5.19B). The key difference: Symbotic Inc is far larger — about 2.4× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| MESO | SYM | |
|---|---|---|
Market Cap | $2.17B | $5.19B |
Sector | Technology | Technology |
52-Week High | $20.96 | $87.30 |
52-Week Low | $12.88 | $38.57 |
Enterprise Value | $2.17B | $3.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Symbotic (SYM) trades at $40.83, down 1.02% recently, with a bearish technical signal and key support at $40. The company reported revenue of $2.25 billion in 2025 but a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights its acquisition of ARMS Innovations and upcoming Q3 2026 earnings on August 5, 2026, amid growing interest in warehouse automation.
Analyst consensus is bullish with a $57.50 price target, but risks include persistent net losses, high EV/EBITDA of 219.3, and competitive pressures. The stock offers growth potential from AI-driven warehouse automation demand, yet profitability challenges and market volatility pose significant headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
